Document is current
Any future updates will be listed below
-
Authors
Kyriakopoulou, Eirini https://orcid.org/0000-0002-4815-5832
Versteeg, Danielle
de Ruiter, Hesther
Perini, Ilaria
Seibertz, Fitzwilliam https://orcid.org/0000-0002-8554-5186
Döring, Yannic
Zentilin, Lorena
Tsui, Hoyee https://orcid.org/0000-0001-7834-6034
van Kampen, Sebastiaan J.
Tiburcy, Malte
Meyer, Tim
Voigt, Niels https://orcid.org/0000-0001-8230-2341
Tintelen, van J. Peter https://orcid.org/0000-0003-3854-6749
Zimmermann, Wolfram H.
Giacca, Mauro https://orcid.org/0000-0003-2927-7225
van Rooij, Eva https://orcid.org/0000-0002-2026-9408
- License Information
-
More Information
Article History
Received: 19 May 2023
Accepted: 27 October 2023
First Online: 7 December 2023
Competing interests
: E.v.R. is a consultant for Tenaya Therapeutics and Novo Nordisk and is Chief Scientific Officer of Phlox Therapeutics. M.T., T.M. and W.H.Z. are inventors of patents related to the EHM technology and scientific advisors to myriamed GmbH. W.H.Z. is founder and shareholder of myriamed GmbH. M.G. is founder, consultant, member of the Board and equity holder in Purespring Therapeutics, Forcefield Therapeutics and Heqet Therapeutics. All other authors declare that they have no competing interests.
